Comparative Efficacy of Adjuvant Chemotherapy Regimens for Breast Cancer: A Study on Cyclophosphamide and Doxorubicin (AC) Versus Paclitaxel (T) and the Impact of Biological Characteristics

Ji Zhang; Xinqi Zhou; Ruolin Sun

doi:10.54254/2753-8818/2024.19989

Article Information

Received: 27 September 2024

Published: 10 January 2025

DOI: https://doi.org/10.54254/2753-8818/2024.19989

Article Type: Research Article

Cite this article

Zhang,J.;Zhou,X.;Sun,R. (2025). Comparative Efficacy of Adjuvant Chemotherapy Regimens for Breast Cancer: A Study on Cyclophosphamide and Doxorubicin (AC) Versus Paclitaxel (T) and the Impact of Biological Characteristics. Theoretical and Natural Science,78,235-244.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About this Volume

Volume Title: TNS Vol.78

Part of Series: Theoretical and Natural Science

ISSN: 2753-8818 (Print) / 2753-8826 (Online)

Copyright & License

[1]Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https://gco.iarc.who.int/today, accessed [21/07/2024].

[2]Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (London, England), 365(9472), 1687–1717.

[3]Cardoso, F., van't Veer, L. J., Bogaerts, J., Slaets, L., Viale, G., Delaloge, S., Pierga, J. Y., Brain, E., Causeret, S., DeLorenzi, M., Glas, A. M., Golfinopoulos, V., Goulioti, T., Knox, S., Matos, E., Meulemans, B., Neijenhuis, P. A., Nitz, U., Passalacqua, R., Ravdin, P., … MINDACT Investigators (2016). 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. The New England journal of medicine, 375(8), 717–729.

[4]Clifford A. Hudis, Luca Gianni, Triple‐Negative Breast Cancer: An Unmet Medical Need, The Oncologist, Volume 16, Issue S1, January 2011, Pages 1–11

[5]Abu Samaan, T. M., Samec, M., Liskova, A., Kubatka, P., & Büsselberg, D. (2019). Paclitaxel’s mechanistic and clinical effects on breast cancer. Biomolecules, 9(12), 789.

[6]R Buzzoni et al., Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.. JCO 9, 2134-40(1991).

[7]Kimura, M., Sano, M., Fujimori, M., Nakagomi, H., Negishi, T., Yanagita, Y., & Sato, N. (2008). Neoadjuvant paclitaxel for operable breast cancer: multicenter phase II trial with clinical outcomes. Anticancer research, 28(2B), 1239–1244.

[8]Biganzoli, L., Cufer, T., Bruning, P., Coleman, R., Duchateau, L., Calvert, A. H., Gamucci, T., Twelves, C., Fargeot, P., Epelbaum, R., Lohrisch, C., & Piccart, M. J. (2002). Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 20(14), 3114–3121.

[9]Diéras, V., Fumoleau, P., Romieu, G., Tubiana-Hulin, M., Namer, M., Mauriac, L., Guastalla, J. P., Pujade-Lauraine, E., Kerbrat, P., Maillart, P., Pénault-Llorca, F., Buyse, M., & Pouillart, P. (2004). Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22(24), 4958–4965.

[10]Jones, S. E., Savin, M. A., Holmes, F. A., O'Shaughnessy, J. A., Blum, J. L., Vukelja, S., McIntyre, K. J., Pippen, J. E., Bordelon, J. H., Kirby, R., Sandbach, J., Hyman, W. J., Khandelwal, P., Negron, A. G., Richards, D. A., Anthony, S. P., Mennel, R. G., Boehm, K. A., Meyer, W. G., & Asmar, L. (2006). Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24(34), 5381–5387.

[11]Saura, C., Tseng, L. M., Chan, S., Chacko, R. T., Campone, M., Manikhas, A., Nag, S. M., Leichman, C. G., Dasappa, L., Fasching, P. A., Hurtado de Mendoza, F., Symmans, W. F., Liu, D., Mukhopadhyay, P., Horak, C., Xing, G., & Pusztai, L. (2013). Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker. The oncologist, 18(7), 787–794. https://doi.org/10.1634/theoncologist.2013-0075

[12]Rau, K. M., Lin, Y. C., Chen, Y. Y., Chen, J. S., Lee, K. D., Wang, C. H., & Chang, H. K. (2015). Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study. BMC cancer, 15, 423. https://doi.org/10.1186/s12885-015-1433-4

[13]Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., Perez, E. A., Carpenter, J., Hurd, D., Holland, J. F., Smith, B. L., Sartor, C. I., Leung, E. H., Abrams, J., Schilsky, R. L., Muss, H. B., … Norton, L. (2003). Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21(8), 1431–1439.

[14]Gui, J., Mustachio, L. M., Su, D. M., & Craig, R. W. (2012). Thymus Size and Age-related Thymic Involution: Early Programming, Sexual Dimorphism, Progenitors and Stroma. Aging and disease, 3(3), 280–290.

[15]Fulop, T., Witkowski, J. M., Olivieri, F., & Larbi, A. (2018, December). The integration of inflammaging in age-related diseases. In Seminars in immunology (Vol. 40, pp. 17-35). Academic Press.

[16]Michaelson, J. S., Silverstein, M., Sgroi, D., Cheongsiatmoy, J. A., Taghian, A., Powell, S., ... & Smith, B. (2003). The effect of tumor size and lymph node status on breast carcinoma lethality. Cancer: Interdisciplinary International Journal of the American Cancer Society, 98(10), 2133-2143.

[17]Holliday, D. L., & Speirs, V. (2011). Choosing the right cell line for breast cancer research. Breast cancer research, 13, 1-7.

[18]Kuo, H. T., Que, J., Lin, L. C., Yang, C. C., Koay, L. B., & Lin, C. H. (2017). Impact of tumor size on outcome after stereotactic body radiation therapy for inoperable hepatocellular carcinoma. Medicine, 96(50), e9249.

[19]Kümler, I., Christiansen, O. G., & Nielsen, D. L. (2014). A systematic review of bevacizumab efficacy in breast cancer. Cancer treatment reviews, 40(8), 960-973.

[20]Tewey, K. M., Rowe, T. C., Yang, L., Halligan, B. D., & Liu, L. F. (1984). Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science, 226(4673), 466-468.

[21]Weaver, B. A. (2014). How Taxol/paclitaxel kills cancer cells. Molecular biology of the cell, 25(18), 2677-2681

[22]Abal, M., Andreu, J. M., & Barasoain, I. (2003). Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Current cancer drug targets, 3(3), 193-203.

[23]Gérard, C., & Goldbeter, A. (2014). The balance between cell cycle arrest and cell proliferation: control by the extracellular matrix and by contact inhibition. Interface focus, 4(3), 20130075.

[24]Stanton, R. A., Gernert, K. M., Nettles, J. H., & Aneja, R. (2011). Drugs that target dynamic microtubules: a new molecular perspective. Medicinal research reviews, 31(3), 443-481.

[25]Dunnwald, Lisa K., Mary Anne Rossing, and Christopher I. Li. "Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients." Breast cancer research 9 (2007): 1-10.

[26]Bardou, Valerie-Jeanne, et al. "Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases." Journal of clinical oncology21.10 (2003): 1973-1979.

[27]Lower, Elyse E., et al. "Impact of metastatic estrogen receptor and progesterone receptor status on survival." Breast cancer research and treatment 90 (2005): 65-70.

[28]Fan W, Chang J, Fu P. Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies. Future Med Chem. 2015;7(12):1511–1519. doi:10.4155/fmc.15.93

[29]Nahleh, Z. (2008). Androgen Receptor As A Target For the Treatment of Hormone Receptor-Negative Breast Cancer: An Unchartered Territory. Future Oncology, 4(1), 15–21.

[30]Cooper GM. The Cell: A Molecular Approach. 2nd edition. Sunderland, MA: Sinauer Associates; 2000.

[31]Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., & Ullrich, A. (1989). Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (New York, N.Y.), 244(4905), 707–712.

[32]Native Hawaiian women and the experience of breast cancer.Lau, B., Tominez, P., Shing, J. Z., Vo, J. B., Pollom, E., & Taparra, K. (2023). Racial disparities among Asian American, Native Hawaiian, and other Pacific Islander Patients with cancer who refuse recommended radiation therapy or surgery. Cancers, 15(13), 3358.)

[33]Eide P. (2006). Native Hawaiian women and the experience of breast cancer. Women & health, 44(4), 41–59.

[34]Palmer, D. B. (2013). The effect of age on thymic function. Frontiers in Immunology, 4, 316.

[35]Aubert, G., & Lansdorp, P. M. (2008). Telomeres and aging. Physiological reviews, 88(2), 557–579.

[36]Gunasekaran, G.H., Hassali, M.A.B.A., Sabri, W.M.A.B.W. et al. Impact of chemotherapy schedule modification on breast cancer patients: a single-centre retrospective study. Int J Clin Pharm 42, 642–651 (2020).

[37]Rakha, Emad A., et al. "Breast cancer prognostic classification in the molecular era: the role of histological grade." Breast cancer research 12 (2010): 1-12.

[38]Henson, Donald Earl, et al. "Relationship among outcome, stage of disease, and histologic grade for 22,616 cases of breast cancer. The basis for a prognostic index." Cancer 68.10 (1991): 2142-2149.